公开(公告)号：US20250134895A1

公开(公告)日：2025-05-01

申请号：US18684053

申请日：2022-08-16

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Lorraine V. Kalia ,  Suneil K. Kalia

IPC: A61K31/52 ,  A61K31/4178 ,  A61K31/436 ,  A61K31/438 ,  A61K31/513 ,  A61P25/28

Abstract: Provided is a method of treating a subject with an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, a method of treating a subject with a high risk of developing an α-synucleinopathy neurodegenerative disorder, the method comprising administering one or more therapeutic(s) to the subject, wherein the one or more therapeutic(s) is or comprise rifabutin, one or more nucleoside analog reverse transcriptase inhibitor(s), optionally selected from lamivudine, emtricitabine, tenofovir disoproxil funiarate, tenofovir alafenamide, abacavir, zidovudine, didanosine, and/or stavudine, losartan, or a combination thereof.

公开(公告)号：US20250051391A1

公开(公告)日：2025-02-13

申请号：US18720385

申请日：2022-12-15

Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO ,  UNIVERSITY HEALTH NETWORK

Inventor： Philip Kim ,  Satra Nim ,  Carlos Corbi Verge ,  Suneil K. Kalia ,  Lorraine V. Kalia

IPC: C07K7/06 ,  A61K38/00 ,  A61P25/28 ,  C07K7/08

Abstract: Provided herein is a method of decreasing a-syn levels and/or decreasing a-syn toxicity in a cell, the method comprising contacting the cell with a charged multivesicular body protein 2B: a-synuclein (CHMP2B:a-syn) inhibitor and a method of inhibiting neural degeneration, the method comprising administering to a subject in need thereof a charged multivesicular body protein 2B: a-synuclein (CHMP2B:a-syn) inhibitor.